Europe is at risk of losing one of the last jewels in its industrial crown. The innovative pharmaceutical sector is being pulled into the crossfire of a volatile geopolitical age, while indifference at home threatens to undervalue an industry central to Europe’s economic strength, social resilience and public health security
It is a situation likely to be exacerbated by the United States’ Most-Favored-Nation pricing policy, which calls for a new perspective on how Europe can create the right ecosystem to strengthen a strategic industry.
Christophe Bourdon, CEO, LEO Pharma
As a European having worked in the industry across the world, I have seen how quickly biotech and drug discovery are moving in both China and the United States. A recent trip to China made clear just how fast the pace now is in artificial intelligence, biotechnology, digital health and clinical research. Europe, by contrast, has lost momentum. The gap is widening fast; the time to act is now.
A gap Europe can no longer ignore
